Shares of uniQure NV (NASDAQ:QURE) were up 7.8% on Monday . The company traded as high as $8.86 and last traded at $8.85, with a volume of 276,976 shares traded. The stock had previously closed at $8.21.

A number of analysts have weighed in on QURE shares. WallachBeth Capital decreased their price target on uniQure NV from $60.00 to $35.00 and set a “buy” rating for the company in a report on Wednesday, June 15th. Cowen and Company reiterated a “buy” rating on shares of uniQure NV in a report on Tuesday, June 14th. Leerink Swann reiterated a “buy” rating on shares of uniQure NV in a report on Sunday, June 12th. Piper Jaffray Cos. reiterated a “buy” rating on shares of uniQure NV in a report on Monday, June 13th. Finally, Jefferies Group reiterated a “buy” rating on shares of uniQure NV in a report on Tuesday, May 31st. One research analyst has rated the stock with a sell rating and ten have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $28.10.

The firm’s 50-day moving average is $7.88 and its 200 day moving average is $11.30. The firm’s market cap is $209.47 million.

uniQure NV (NASDAQ:QURE) last posted its earnings results on Tuesday, May 31st. The company reported ($0.93) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by $0.10. Equities analysts expect that uniQure NV will post ($3.50) earnings per share for the current year.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.